Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Operating Leases: 2020-2024

Historic Operating Leases for Relay Therapeutics (RLAY) over the last 5 years, with Dec 2024 value amounting to $42.8 million.

  • Relay Therapeutics' Operating Leases fell 32.97% to $29.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.7 million, marking a year-over-year decrease of 32.97%. This contributed to the annual value of $42.8 million for FY2024, which is 11.81% down from last year.
  • Per Relay Therapeutics' latest filing, its Operating Leases stood at $42.8 million for FY2024, which was down 11.81% from $48.5 million recorded in FY2023.
  • Relay Therapeutics' 5-year Operating Leases high stood at $53.5 million for FY2022, and its period low was $21.1 million during FY2021.
  • Its 3-year average for Operating Leases is $48.2 million, with a median of $48.5 million in 2023.
  • As far as peak fluctuations go, Relay Therapeutics' Operating Leases skyrocketed by 153.92% in 2022, and later dropped by 11.81% in 2024.
  • Yearly analysis of 5 years shows Relay Therapeutics' Operating Leases stood at $22.9 million in 2020, then declined by 8.06% to $21.1 million in 2021, then skyrocketed by 153.92% to $53.5 million in 2022, then fell by 9.28% to $48.5 million in 2023, then fell by 11.81% to $42.8 million in 2024.